文献速递产科母胎医学

17-羟孕酮己酸酯的给药方案欠佳:对孕妇未来药物治疗研究的启示

The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
PubMed 文献 · Am J Obstet Gynecol · 2024-04-25

该研究分析三项数据集评估17-羟孕酮己酸酯给药方案,发现自发早产风险随药物对数浓度升高而降低(OR 0.04),稳态浓度>9 ng/mL时风险最低(HR 0.52),但250 mg每周剂量下25%受试者未达到该浓度,提示给药方案不充分。

要点

  • 自发早产风险随17-羟孕酮己酸酯对数浓度升高而降低(OR 0.04,95%CI 0.00-0.90)。
  • 稳态浓度>9 ng/mL与自发早产风险最低相关(HR 0.52,95%CI 0.27-0.98,P=.04)。
  • 250 mg每周剂量下25%受试者未达到9 ng/mL,需负荷剂量快速达标。

核心结论

  • 17-羟孕酮己酸酯的给药方案不充分,药物浓度与自发早产呈显著负相关,浓度超过9 ng/mL时风险最低,但250 mg每周剂量下25%女性从未达到或维持该浓度;药物半衰期长需负荷剂量以快速达到治疗浓度;省略基础药理学研究确定合适剂量可能损害了17-羟孕酮己酸酯的有效性;未来妊娠期药物治疗试验必须首先完成基础药理学研究。

研究设计与样本

  • 本研究分析三个评估17-羟孕酮己酸酯药理学的研究数据集:母胎医学Omega 3研究、产科-胎儿药理学研究单位研究和产科-胎儿药理学研究中心研究。

主要发现

  • Omega 3数据集分析表明,自发早产风险随17-羟孕酮己酸酯对数浓度增加而降低(比值比0.04;95%置信区间0.00-0.90)。
  • 稳态浓度>9 ng/mL(相当于25-28周时>8 ng/mL)与自发早产风险最低相关(风险比0.52;95%置信区间0.27-0.98;P=.04);接受250 mg每周剂量的受试者中25%未达到该浓度。
  • 在产科-胎儿药理学研究单位研究中,17-羟孕酮己酸酯的校正半衰期(中位数和四分位距)为14.0(11.5-17.2)天;模拟表明250 mg每周剂量下需要>5次每周注射才能达到9 ng/mL目标,但半衰期最短者(对应更高清除率)从未达到目标9 ng/mL浓度。
  • 在75%受试者中,500 mg每周负荷剂量2周后接250 mg每周可在2周内达到并维持9 ng/mL浓度,但在半衰期最短的25%受试者中,浓度仅超过9 ng/mL目标3周。
  • 在产科-胎儿药理学研究中心研究中,所有65名接受500 mg每周剂量的受试者均超过9 ng/mL稳态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Makena (17-hydroxyprogesterone caproate) was approved by the United States Food and Drug Administration for the prevention of recurrent spontaneous preterm birth in 2011 under the accelerated approval pathway, but fundamental pharmacokinetic or pharmacodynamic (Phase 1 and Phase 2) studies were not performed. At the time, there were no dose-response or concentration-response data. The therapeutic concentration was not known. The lack of such data brings into question the dosing regimen for 17-hydroxyprogesterone caproate and if it was optimized. OBJECTIVE: The purpose of this study was to evaluate the dosing regimen for 17-hydroxyprogesterone by analyzing 3 data sets in which the 17-hydroxyprogesterone caproate pharmacology was evaluated, namely the Maternal-Fetal Medicine Omega 3 study, the Obstetric-Fetal Pharmacology Research Units study, and the Obstetrical-Fetal Pharmacology Research Centers study. If an inappropriate dosing regimen could be identified, such information could inform future studies of pharmacotherapy in pregnancy. STUDY DESIGN: Data from the Omega 3 study were used to determine if plasma concentration was related to spontaneous preterm birth risk and if a threshold concentration could be identified. Data from the Obstetric-Fetal Pharmacology Research Units study were used to determine the half-life of 17-hydroxyprogesterone caproate and to develop a model to simulate drug concentrations with various dosing regimens. Data from the Obstetrical-Fetal Pharmacology Research Centers study were used to determine the relationship between dose and safety outcomes. RESULTS: Analysis of the Omega 3 data set indicated that the risk for spontaneous preterm birth decreased as the log concentration of 17-hydroxyprogesterone caproate increased (odds ratio, 0.04; 95% confidence interval, 0.00-0.90). A steady state concentration of >9 ng/mL (equivalent to >8 ng/mL at 25-28 weeks) was associated with the lowest risk for spontaneous preterm birth (hazard ratio, 0.52; 95% confidence interval, 0.27-0.98; P=.04); this concentration was not achieved in 25% of subjects who received the 250 mg weekly dose. In the Obstetrical-Fetal Pharmacology Research Units study, the adjusted half-life (median and interquartile range) of 17-hydroxyprogesterone caproate was 14.0 (11.5-17.2) days. Simulations indicated that with the 250 mg weekly dose, >5 weekly injections were required to reach the 9 ng/mL target; however, those with the shortest half-life (corresponding to higher clearance), never reached the targeted 9 ng/mL concentration. In 75% of subjects, a loading dose of 500 mg weekly for 2 weeks followed by 250 mg weekly achieved and maintained the 9 ng/mL concentration within 2 weeks but in those 25% with the shortest half-life, concentrations exceeded the 9 ng/mL target for only 3 weeks. In the Obstetrical-Fetal Pharmacology Research Centers study, all 65 subjects who received a weekly dose of 500 mg exceeded the 9 ng/mL steady state. CONCLUSION: The dosing regimen for 17-hydroxyprogesterone caproate was inadequate. There is a significant inverse relationship between drug concentration and spontaneous preterm birth. The risk was lowest when the concentration exceeded 9 ng/mL, but 25% of women who received the 250 mg weekly dose never reached or maintained this concentration. The drug's long half-life necessitates a loading dose to achieve therapeutic concentrations rapidly. The omission of basic pharmacologic studies to determine the proper dosing may have compromised the effectiveness of 17-hydroxyprogesterone caproate. Future pharmacotherapy trials in pregnancy must first complete fundamental pharmacology studies.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Caritis SN, Dodeja P, Sharma S, et al. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women. Am J Obstet Gynecol. 2024. PMID: 38670444. doi:10.1016/j.ajog.2024.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。